Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 65
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency | ||
| NCT02176863 | Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome | ||
| NCT00220740 | Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | ||
| NCT04055389 | Preventing de Novo Portal Vein Thrombosis With Antithrombin-III in Patients With Cirrhosis | ||
| NCT04547140 | Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) | ||
| NCT04566692 | A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency | ||
| NCT03451292 | Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites | ||
| NCT02472665 | Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease | ||
| NCT02473965 | Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis | ||
| NCT01201720 | Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure" | ||
| NCT02413580 | A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations | ||
| NCT00220766 | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients | ||
| NCT00301366 | The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency | ||
| NCT01051544 | Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive | ||
| NCT02872142 | Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis | ||
| NCT03461406 | A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants | ||
| NCT01757418 | Intravenous Gammaglobulin for Sickle Cell Pain Crises | ||
| NCT02093221 | Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus | ||
| NCT00220779 | Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis | ||
| NCT02037555 | Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass | ||
| NCT01213043 | Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin Deficiency | ||
| NCT04636268 | FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis | ||
| NCT01684410 | Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis | ||
| NCT00968695 | Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites. | ||
| NCT02604810 | Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency | ||
| NCT03095287 | Alphanate in Immune Tolerance Induction Therapy | ||
| NCT01014975 | A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients | ||
| NCT02796937 | Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency | ||
| NCT02473952 | A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis | ||
| NCT04495101 | Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19 | ||
| NCT04547127 | A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19) | ||
| NCT02282527 | A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency | ||
| NCT01051076 | Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) | ||
| NCT00417573 | Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections | ||
| NCT00220727 | Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP | ||
| NCT02870348 | Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE) | ||
| NCT01380626 | Effects of Exercise Training in Chronic Obstructive Pulmonary Disease Versus Alpha-1-Antitrypsin-deficiency-patients | ||
| NCT01222117 | A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion | ||
| NCT01465958 | Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency | ||
| NCT01841619 | IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus | ||
| NCT00606905 | Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage | ||
| NCT00295061 | Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults | ||
| NCT00220805 | Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration | ||
| NCT03814798 | Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency | ||
| NCT02870309 | Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency | ||
| NCT05645107 | A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | ||
| NCT00437671 | Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels | ||
| NCT01179893 | Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis | ||
| NCT00418483 | A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion | ||
| NCT04722887 | A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency |
